Bristol-Myers Squibb Company and Pfizer announced that eight abstracts have been accepted for presentation at the American College of Cardiology (ACC) 66thAnnual Scientific Session, taking place March 17-19 in Washington, D.C. In addition to post-hoc analyses from the pivotal Phase 3 ARISTOTLE (Apixaban for Reduction In STroke and Other ThromboemboLic Events in Atrial Fibrillation) trial, the Bristol-Myers Squibb and Pfizer Alliance will present real-world data analyses that illustrate the Alliance’s ongoing commitment to understanding the use of direct oral anticoagulants, including Eliquis™ (apixaban), in routine clinical practice. This real-world research, part of the global ACROPOLIS™ (Apixaban ExperienCe Through Real-WOrld POpuLatIon Studies) program, aims to complement findings from clinical trials and contribute to the growing body of knowledge around anticoagulation.
In a Late-Breaking Clinical Trials session, the Alliance will highlight a post-hoc analysis from the ARISTOTLE trial, titled ARISTOTLE: Digoxin and Mortality in Patients with Atrial Fibrillation with and without Heart Failure: Does Serum Digoxin Concentration Matter? Results of the analysis will be presented on March 19 at 11:00 a.m. Eastern Daylight Time.
“During ACC, the Bristol-Myers Squibb and Pfizer Alliance will share several analyses that delve deeper into the robust data generated from the ARISTOTLE study,” said Christoph Koenen, M.D., MBA, VP, Development Lead, Eliquis, Bristol-Myers Squibb. “Through continued analyses and support of the ARISTOTLE trial, we can examine topics such as outcomes for patients with different comorbidities and the potential treatment effects of interacting drugs, which expands our scientific understanding.”
“As physicians evaluate options for reducing stroke risk in patients with non-valvular atrial fibrillation, they often face questions about the effectiveness and safety of therapies in day-to-day practice,” said Rory O’Connor, M.D., Chief Medical Officer, Pfizer Innovative Health. “Real-world data analyses allow us to explore the usage of Eliquis and anticoagulants across various geographies and subgroups of patients. Alongside clinical data, the real-world data analyses we are presenting during ACC have the potential to help healthcare providers make more informed decisions along with their patients.”
Below is a complete list of Bristol-Myers and Pfizer Alliance presentations during ACC. Abstracts can be accessed through the ACC.17 Online Program Planner.
| Title | Presenting Author/Type | Date/Time (EDT) | Location/Session |
| Phase 3 Clinical Trial Post-Hoc Analyses | |||
|
ARISTOTLE: Digoxin and Mortality in Patients with Atrial Fibrillation with and without Heart Failure: Does Serum Digoxin Concentration Matter? Session: Late-Breaking Clinical Trials |
Lopes et al./
Late-Breaker |
Mar. 19, 11:00 AM | Late-Breaking Clinical Trials, ACC.17 Main Tent, Hall D |
| Use of Interacting Drugs Did Not Modify Treatment Effects of Apixaban Versus Warfarin for Atrial Fibrillation: Results from the ARISTOTLE Trial
Session: Arrhythmias and Clinical EP: Anticoagulation Issues |
Washam et al./
Poster |
Mar. 18,
9:45 AM |
Poster Hall, Hall C |
| Aortic Stenosis, but Not Mitral or Aortic Regurgitation, Associated with Adverse Outcomes with Atrial Fibrillation: Results from the ARISTOTLE Trial
Session:Arrhythmias and Clinical EP: AF Miscellaneous and Surgical Issues |
Wang et al./ Poster |
Mar. 18,
3:45 PM |
Poster Hall, Hall C |
| Real-World Data and Other Analyses | |||
|
Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Compared to Warfarin among Non-Valvular Atrial Fibrillation Patients in the US Medicare Population Session: Atrial Fibrillation, Anticoagulation and Novel Device Therapies |
Amin et al./
Moderated Poster |
Mar. 17, 11:15 AM | Arrhythmias and Clinical EP Moderated Poster Theater, Poster Hall, Hall C |
| Real World Evaluation of Major Bleeding Risk and Costs for All Causes and Bleeding-related Health Services among Elderly Patients with Nonvalvular Atrial Fibrillation Treated with Apixaban or Warfarin
Session: Atrial Fibrillation, Anticoagulation and Novel Device Therapies |
Deitelzweig et al./ Moderated Poster | Mar. 17, 10:15 AM | Arrhythmias and Clinical EP Moderated Poster Theater, Poster Hall, Hall C |
| Real-World Comparison of Major Bleeding and Associated Costs among Oral Anticoagulant-naïve Non-valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin in the US Medicare Population
Session: Arrhythmias and Clinical EP: Anticoagulation Issues |
Amin et al./ Poster | Mar. 18,
9:45 AM |
Poster Hall, Hall C |
| Bleeding Risk among Japanese Non-valvular Atrial Fibrillation Patients Initiated on Apixaban, Dabigatran, Rivaroxaban or Warfarin in the Real World
Session: Arrhythmias and Clinical EP: Anticoagulation Issues |
Wang et al./ Poster |
Mar. 18,
9:45 AM |
Poster Hall, Hall C |
| What are the Differences in Oral Anticoagulant Treatment Persistence in Non-Valvular Atrial Fibrillation in Europe? Real-World Studies in Three European Countries
Session:Innovative Approaches for Reducing Risk and Improving Outcomes With Ablation |
Fauchier et al./
Poster |
Mar. 18,
3:45 PM |
Poster Hall, Hall C |
Filed Under: Drug Discovery
